Recent MIRA News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/26/2024 08:55:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/26/2024 08:49:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:07:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 09:12:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 09:00:40 PM
- MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing • PR Newswire (US) • 06/24/2024 12:30:00 PM
- Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year • PR Newswire (US) • 06/10/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 10:00:06 PM
- Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance • PR Newswire (US) • 05/29/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 12:30:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 09:42:53 PM
- MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog • PR Newswire (US) • 05/21/2024 12:45:00 PM
- Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog • PR Newswire (US) • 05/20/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:31:03 PM
- Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission • PR Newswire (US) • 04/02/2024 12:00:00 PM
- MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor • PR Newswire (US) • 03/21/2024 03:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:45:16 PM
- MIRA Pharmaceuticals Provides Corporate Update • PR Newswire (US) • 02/05/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:30:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/28/2023 05:15:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 10:33:10 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/27/2023 10:27:24 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/18/2023 09:50:37 PM
- MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations • PR Newswire (US) • 12/04/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 10:00:35 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM